MA38724B1 - Formulation liquide stable d'amg 416 (velcalcétide) - Google Patents

Formulation liquide stable d'amg 416 (velcalcétide)

Info

Publication number
MA38724B1
MA38724B1 MA38724A MA38724A MA38724B1 MA 38724 B1 MA38724 B1 MA 38724B1 MA 38724 A MA38724 A MA 38724A MA 38724 A MA38724 A MA 38724A MA 38724 B1 MA38724 B1 MA 38724B1
Authority
MA
Morocco
Prior art keywords
velcalctide
amg
liquid formulation
stable liquid
formulation
Prior art date
Application number
MA38724A
Other languages
English (en)
Other versions
MA38724A1 (fr
Inventor
Derek Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38724(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA38724A1 publication Critical patent/MA38724A1/fr
Publication of MA38724B1 publication Critical patent/MA38724B1/fr

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation liquide comprenant un agoniste peptidique du récepteur sensible au calcium, et un procédé de préparation et d'utilisation de cette formulation.
MA38724A 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide) MA38724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (fr) 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide)

Publications (2)

Publication Number Publication Date
MA38724A1 MA38724A1 (fr) 2017-03-31
MA38724B1 true MA38724B1 (fr) 2017-11-30

Family

ID=51213030

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38724A MA38724B1 (fr) 2013-06-28 2014-06-27 Formulation liquide stable d'amg 416 (velcalcétide)

Country Status (38)

Country Link
US (4) US9820938B2 (fr)
EP (3) EP3013318B1 (fr)
JP (1) JP6027708B2 (fr)
KR (1) KR102231957B1 (fr)
CN (2) CN105764487A (fr)
AP (1) AP2015008936A0 (fr)
AR (1) AR096773A1 (fr)
AU (1) AU2014302122B2 (fr)
CA (1) CA2916222C (fr)
CL (1) CL2015003738A1 (fr)
CR (2) CR20160002A (fr)
CY (1) CY1120811T1 (fr)
DK (1) DK3013318T3 (fr)
EA (1) EA030220B1 (fr)
ES (1) ES2633989T3 (fr)
HK (1) HK1222557A1 (fr)
HR (1) HRP20171092T1 (fr)
HU (1) HUE034209T2 (fr)
IL (1) IL243210B (fr)
JO (1) JO3817B1 (fr)
LT (1) LT3013318T (fr)
MA (1) MA38724B1 (fr)
ME (1) ME02818B (fr)
MX (1) MX2015017952A (fr)
MY (1) MY180276A (fr)
PE (2) PE20160549A1 (fr)
PH (1) PH12015502816B1 (fr)
PL (1) PL3013318T3 (fr)
PT (1) PT3013318T (fr)
RS (1) RS56238B1 (fr)
SG (1) SG11201510647TA (fr)
SI (1) SI3013318T1 (fr)
TN (1) TN2015000569A1 (fr)
TW (1) TWI635874B (fr)
UA (1) UA115373C2 (fr)
UY (1) UY35636A (fr)
WO (1) WO2014210489A1 (fr)
ZA (1) ZA201600238B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013318B1 (fr) 2013-06-28 2017-04-19 Amgen Inc. Formulation liquide stable d'amg 416 (velcalcétide)
IL248059B2 (en) 2014-04-03 2023-10-01 Amgen Inc Method for preparing AMG 416
EP3274360B1 (fr) * 2015-03-26 2020-05-06 Amgen Inc. Procédé de préparation d'ételcalcétide en phase soluble
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
EP4149507A1 (fr) 2020-05-15 2023-03-22 Amgen Inc. Méthodes de traitement de l'hypertrophie ventriculaire gauche
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (fr) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Formulations d'ételcalcetide à usage parentéral
JP2024517801A (ja) 2021-05-06 2024-04-23 アムジエン・インコーポレーテツド エテルカルセチド製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69703121D1 (de) 1996-10-25 2000-10-19 Us Health Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
ES2380437T3 (es) * 2003-06-03 2012-05-11 Novo Nordisk A/S Composiciones farmacéuticas de péptido GLP-1 estabilizadas
CA2527743A1 (fr) 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
WO2008067199A2 (fr) 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Peptides modulateurs du calcium polycationique pour le traitement des troubles de l'hyperparathyroïdie et l'hypercalcémie
KR102274003B1 (ko) * 2007-01-19 2021-07-08 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
EP2264138B2 (fr) 2009-06-19 2023-03-08 The Procter & Gamble Company Composition de détergent liquide pour lavage de la vaisselle à la main
CN102711789B (zh) * 2009-07-29 2018-06-08 凯伊药品公司 用于降低甲状旁腺激素水平的治疗剂
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
WO2012075375A1 (fr) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Administration d'hormones parathyroïdiennes par des systèmes de micro-injection
PT2717896T (pt) 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
US20140315809A1 (en) * 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
EP3013318B1 (fr) 2013-06-28 2017-04-19 Amgen Inc. Formulation liquide stable d'amg 416 (velcalcétide)
IL248059B2 (en) * 2014-04-03 2023-10-01 Amgen Inc Method for preparing AMG 416

Also Published As

Publication number Publication date
SG11201510647TA (en) 2016-01-28
IL243210A0 (en) 2016-02-29
PH12015502816A1 (en) 2016-03-21
LT3013318T (lt) 2017-09-11
TW201542239A (zh) 2015-11-16
MY180276A (en) 2020-11-26
EP3013318A1 (fr) 2016-05-04
JP6027708B2 (ja) 2016-11-16
TN2015000569A1 (en) 2017-04-06
US20180080452A1 (en) 2018-03-22
IL243210B (en) 2020-02-27
ZA201600238B (en) 2017-05-31
CL2015003738A1 (es) 2016-12-09
ES2633989T3 (es) 2017-09-26
EP3878433A1 (fr) 2021-09-15
JO3817B1 (ar) 2021-01-31
CY1120811T1 (el) 2019-12-11
US11162500B2 (en) 2021-11-02
CR20160061A (es) 2016-09-28
CA2916222A1 (fr) 2014-12-31
SI3013318T1 (sl) 2017-11-30
EP3013318B1 (fr) 2017-04-19
BR112015032615A2 (pt) 2017-07-25
JP2016523916A (ja) 2016-08-12
KR102231957B1 (ko) 2021-03-25
DK3013318T3 (en) 2017-08-07
EA201690099A1 (ru) 2016-06-30
HUE034209T2 (en) 2018-02-28
US10344765B2 (en) 2019-07-09
AR096773A1 (es) 2016-02-03
PT3013318T (pt) 2017-07-24
MA38724A1 (fr) 2017-03-31
CN105764487A (zh) 2016-07-13
AU2014302122B2 (en) 2018-12-06
PL3013318T3 (pl) 2018-03-30
CN114376970A (zh) 2022-04-22
RS56238B1 (sr) 2017-11-30
NZ715403A (en) 2020-10-30
CR20160002A (es) 2018-02-13
KR20160043954A (ko) 2016-04-22
PH12015502816B1 (en) 2016-03-21
US9820938B2 (en) 2017-11-21
US20190285074A1 (en) 2019-09-19
AP2015008936A0 (en) 2015-12-31
UA115373C2 (uk) 2017-10-25
HK1222557A1 (zh) 2017-07-07
PE20160549A1 (es) 2016-06-15
WO2014210489A1 (fr) 2014-12-31
US11959486B2 (en) 2024-04-16
AU2014302122A1 (en) 2016-01-21
EA030220B1 (ru) 2018-07-31
EP3246017A1 (fr) 2017-11-22
PE20210413A1 (es) 2021-03-04
TWI635874B (zh) 2018-09-21
US20160220486A1 (en) 2016-08-04
ME02818B (fr) 2018-01-20
UY35636A (es) 2015-01-30
US20220042515A1 (en) 2022-02-10
EP3246017B1 (fr) 2021-03-24
CA2916222C (fr) 2021-05-18
HRP20171092T1 (hr) 2017-10-06
MX2015017952A (es) 2016-10-28

Similar Documents

Publication Publication Date Title
MA38724A1 (fr) Formulation liquide stable d'amg 416 (velcalcétide)
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
CL2015002098A1 (es) “compuestos derivados de benzotiofeno, antagonistas de receptores de estrógenos y degradantes selectivos de éstos (sreds); composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer de mamas, ovarios, endometrial, próstata, uterino, cervical y pulmones”. pct
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2015016825A (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculos y sus usos.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201491959A1 (ru) Агонистические пептиды для par4
CL2014001871A1 (es) Compuestos derivados de espiroindolina sustituidos, antagonistas del receptor de la hormona liberadora de gonadotropina (gnrh); y composicion farmaceutica que los comprende.
EA201501123A1 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
AR098556A1 (es) Aparato para procesar información, aparato de difusión y método de recepción
SG10201401467VA (en) Device for determining the location of mechanical elements
SA516370737B1 (ar) Cgrp صيغ لمضادات مستقبل
BR112015028082A2 (pt) ensaio de internalização de receptor de sabor
PH12016500044B1 (en) Vasopressin-2 receptor agonists
MX2017000519A (es) Derivados de azaspiro(4.5)decano sustituido.
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
EA201890377A1 (ru) Конструкция панели для системы туннельной опалубки